vs
Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $93.1M, roughly 1.7× HIVE Digital Technologies Ltd.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -98.1%, a 169.3% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 218.6%).
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
HIVE vs STOK — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.1M | $158.6M |
| Net Profit | $-91.3M | $112.9M |
| Gross Margin | -27.1% | — |
| Operating Margin | — | 70.2% |
| Net Margin | -98.1% | 71.2% |
| Revenue YoY | 218.6% | 3661.1% |
| Net Profit YoY | -234.0% | 528.0% |
| EPS (diluted) | $-0.38 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.1M | — | ||
| Q3 25 | $87.3M | — | ||
| Q2 25 | $45.6M | — | ||
| Q1 25 | — | $158.6M | ||
| Q4 24 | $29.2M | $22.6M | ||
| Q3 24 | $22.6M | — | ||
| Q2 24 | $32.2M | — | ||
| Q4 23 | $22.8M | — |
| Q4 25 | $-91.3M | — | ||
| Q3 25 | $-15.8M | — | ||
| Q2 25 | $35.0M | — | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | $68.2M | $-10.5M | ||
| Q3 24 | $80.0K | — | ||
| Q2 24 | $-18.3M | — | ||
| Q4 23 | $-24.5M | — |
| Q4 25 | -27.1% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | -13.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -43.7% | — | ||
| Q3 24 | -66.1% | — | ||
| Q2 24 | -7.4% | — | ||
| Q4 23 | -52.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | -98.1% | — | ||
| Q3 25 | -18.1% | — | ||
| Q2 25 | 76.8% | — | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | 233.2% | -46.4% | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | -56.7% | — | ||
| Q4 23 | -107.8% | — |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | $0.52 | $-0.15 | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $-0.17 | — | ||
| Q4 23 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $559.3M | $350.1M |
| Total Assets | $624.0M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | $40.5M | $128.0M | ||
| Q3 24 | $31.7M | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $4.5M | — |
| Q4 25 | $559.3M | — | ||
| Q3 25 | $624.6M | — | ||
| Q2 25 | $560.5M | — | ||
| Q1 25 | — | $350.1M | ||
| Q4 24 | $430.9M | $229.0M | ||
| Q3 24 | $275.5M | — | ||
| Q2 24 | $268.6M | — | ||
| Q4 23 | $122.9M | — |
| Q4 25 | $624.0M | — | ||
| Q3 25 | $693.0M | — | ||
| Q2 25 | $628.7M | — | ||
| Q1 25 | — | $406.9M | ||
| Q4 24 | $478.6M | $271.6M | ||
| Q3 24 | $334.7M | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.0M | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.0M | — | ||
| Q3 25 | $-10.6M | — | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | — | $131.8M | ||
| Q4 24 | $-28.5M | $-23.2M | ||
| Q3 24 | $-2.2M | — | ||
| Q2 24 | $-4.4M | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | $-55.5M | $-23.2M | ||
| Q3 24 | $-34.7M | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | -189.9% | -102.7% | ||
| Q3 24 | -153.4% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 92.5% | 0.2% | ||
| Q3 24 | 143.9% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | -0.42× | — | ||
| Q3 24 | -26.94× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
